Skip to main content
Annovis Bio, Inc. logo

Annovis Bio, Inc. — Investor Relations & Filings

Ticker · ANVS ISIN · US03615A1088 LEI · 549300IFBVI51FN3NJ32 US Professional, scientific and technical activities
Open in API
Filings indexed 290 across all filing types
Latest filing 2026-05-20 Capital/Financing Update
Country US United States of America
Listing US ANVS

About Annovis Bio, Inc.

https://www.annovisbio.com/

Annovis Bio, Inc. is a clinical-stage drug platform company that develops therapies for neurodegenerative diseases. The company's primary focus is on conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD). Its lead product candidate, buntanetap, is a translational inhibitor designed to halt the death of nerve cells by targeting the synthesis of multiple neurotoxic proteins. The company's therapeutic approach aims to restore nerve cell function, with the goal of improving cognitive and motor abilities in patients suffering from neurodegeneration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 86% confidence The document is a Form 8-K (Current Report) filed by Annovis Bio, Inc. that discloses the entry into a material definitive underwriting agreement for a public offering of common stock and warrants, describing terms of the offering and expected proceeds. This falls squarely under fundraising and financing activity disclosure – a Capital/Financing Update.
2026-05-20 English
424B5
Share Issue/Capital Change Classification · 87% confidence The document is a Form 424(b)(5) prospectus supplement (and accompanying prospectus) filed under a shelf registration (Form S-3) describing an offering of 7,895,000 shares of common stock and warrants exercisable for 7,105,500 shares, including underwriting terms, use of proceeds, risk factors, and details of the securities. This is the primary offering document for a new equity issuance, which falls squarely under announcements of share issues or capital changes. Therefore the most appropriate classification is ‘Share Issue/Capital Change (SHA).’
2026-05-20 English
424B5
Capital/Financing Update Classification · 85% confidence The document is a detailed SEC registration statement “Prospectus Supplement” on Form S-3 (424B5) describing the terms of a new securities offering, use of proceeds, dilution, underwriting, and related capital-raising information. It is not an annual or interim report, earnings release, management discussion, nor a vote result or proxy; rather, it is the primary document through which the company raises new equity capital. This aligns with a Capital/Financing Update (CAP) as it provides comprehensive details on a fundraising transaction.
2026-05-19 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
FORM 8-K
Regulatory Filings
2026-05-15 English
424B5 - Annovis Bio, Inc. (0001477845) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a registered direct offering of common stock and warrants by Annovis Bio, Inc. It includes detailed terms of the offering, pricing, underwriting arrangements, risk factors, use of proceeds, and legal matters. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act. This type of document is a capital raising disclosure, providing detailed information about a financing transaction involving new share issuance and warrants. It is not an annual or quarterly report, earnings release, management discussion, or any other type of report. It is clearly a Capital/Financing Update as it announces and details a new securities offering and related capital raising activity.
2026-04-09 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.